Overview

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects

Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Arcturus Therapeutics, Inc.
Collaborator:
Novotech CRO